Stereoselective Crystallization of Chiral 3,4-Dimethylphenyl Glycerol Ether Complicated by Plurality of Crystalline Modifications
Source abstract
Abstract
Spontaneous resolution of Pasteur’s salt was historically the first way to obtain pure enantiomers from the racemate. The current increase in interest in the direct racemates resolution during crystallization is largely due to the opened prospects for the industrial application of this approach. The chiral 3-(3,4-dimethylphenoxy) propane-1,2-diol 1 is a synthetic precursor of practically useful amino alcohols, the enantiomers of which exhibit different biological effects. In this work, it was first discovered that racemic diol 1 is prone to spontaneous resolution. However, the crystallization process is complicated by the existence, along with the conglomerate, of two other crystalline forms. Using the differential scanning calorimetry (DSC) approach, methods have been developed to obtain individual metastable phases, and all identified modifications ((R)-1, (R+S)-1, α-rac-1, β-rac-1) were ranked by energy. The IR spectroscopy and powder X-ray diffraction (PXRD) methods demonstrated the identity of the first two forms and their proximity to the third, while β-rac-1 is significantly different from the rest. The crystal structure of the forms (R)-1 and α-rac-1 was established by the single crystal X-ray diffraction (SC-XRD) method. Preliminary information on the structure of β-rac-1 phase was obtained by the PXRD approach. Based on the information received, the experimental conditions for a successful direct resolution of racemic 1 into individual enantiomers by a preferential crystallization procedure were selected.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Crystallization and Solubility Studies · Analytical Chemistry and Chromatography · Molecular spectroscopy and chirality
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov St., 8, 420088 Kazan, Russia
References (48)
Show source-provided references
1. Wagniere, G.H. (2007). On Chirality and the Universal Asymmetry: Reflections on Image and Mirror Image, Wiley-VCH.10.1002/9783906390598 ↗
2. From racemates to single enantiomers—Chiral synthetic drugs over the last 20 years10.1007/128_2006_072 ↗
3. The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds10.1016/j.jpba.2017.07.008 ↗
4. De la Torre, B.G., and Albericio, F. (2019). The pharmaceutical industry in 2018. An analysis of FDA drug approvals from the perspective of molecules. Molecules, 24.10.3390/molecules24040809 ↗
5. Progress to date in the design and operation of continuous crystallization processes for pharmaceutical applications10.1021/acs.oprd.8b00319 ↗
6. Recent developments in the crystallization process: Toward the pharmaceutical industry10.1016/J.ENG.2017.03.022 ↗
7. Processes to separate enantiomers10.1002/anie.201302823 ↗
8. Tamura, R., and Miyata, M. (2015). Chiral discrimination in the solid state: Applications to resolution and deracemization. Advances in Organic Crystal Chemistry, Springer.10.1007/978-4-431-55555-1 ↗
9. Andrushko, V., and Andrushko, N. (2013). Crystallization-Based Separation of Enantiomers. Stereoselective Synthesis of Drugs and Natural Products, John Wiley and Sons, Inc.
10. Strategies in optical resolution: A practical guide10.1016/j.tetasy.2008.02.004 ↗
11. Deracemisations under kinetic and thermodynamic control10.1039/C6ME00088F ↗
12. Stereoselective crystallization as a basis for single-enantiomer drug production10.1002/ceat.201600649 ↗
13. Efficient resolution of enantiomers by coupling preferential crystallization and dissolution. Part 1: Experimental proof of principle10.1021/cg3009943 ↗
14. Efficient resolution of enantiomers by coupling preferential crystallization and dissolution. Part 1: A parametric simulation study to identify suitable process conditions10.1021/cg3018503 ↗
15. Efficient resolution of enantiomers by coupling preferential crystallization and dissolution. Part 2: A parametric simulation study to identify suitable process conditions10.1021/cg500913r ↗
16. Exploiting ternary solubility phase diagrams for resolution of enantiomers: An instructive example10.1002/ceat.201900421 ↗
17. Deracemization in a complex quaternary system with a second-order asymmetric transformation by using phase diagram studies10.1002/chem.201903338 ↗
18. Continuous separation of isomers in fluidized bed crystallizers10.1021/acs.cgd.5b01513 ↗
19. Continuous preferential crystallization of chiral molecules in single and coupled mixed-suspension mixed-product-removal crystallizers10.1021/cg501854g ↗
20. Efficient resolution of racemic guaifenesin via batch-preferential crystallization processes10.1021/acs.oprd.9b00413 ↗
21. Solid state properties and effective resolution procedure for guaifenesin, 3-(2-methoxyphenoxy)-1,2-propanediol10.1016/j.tetasy.2006.10.027 ↗
22. O’Neil, M.J. (2006). The Merck Index, Merck and Co. Inc.. [14th ed.].
23. Synthetic approaches towards the synthesis of beta-blockers (betaxolol, metoprolol, sotalol, and timolol)10.3906/kim-1504-65 ↗
24. Single enantiomeric beta-blockers—The existing technologies10.1016/j.procbio.2010.06.022 ↗
25. Methodologies for the stereoselective synthesis of adrenergic beta-blockers: An overview10.3109/10242420109105262 ↗
26. Crystallization of chiral compounds: Thermodynamical, structural and practical aspects10.1016/j.mencom.2012.06.001 ↗
27. Stereoselective crystallization of 3-(2,6-dimethylphenoxy)propane-1,2-diol: Preparation of the single-enantiomer drug mexiletine10.1016/j.tetasy.2015.04.005 ↗
28. Synthesis, crystal structure, and absolute configuration of the enantiomers of chiral drug xibenolol hydrochloride10.1016/j.tetasy.2017.08.013 ↗
29. Spontaneous resolution of chiral 3-(2,3-dimethyl phenoxy)propane-1,2-diol under the circumstances of an unusual diversity of racemic crystalline modifications10.1021/acs.cgd.7b00510 ↗
30. Solid phase behavior, polymorphism, and crystal structure features of chiral drug metaxalone10.1021/acs.cgd.8b00874 ↗
31. Nonracemic dimethylphenyl glycerol ethers in the synthesis of physiologically active aminopropanols10.1134/S1070428019060149 ↗
32. The design, synthesis and pharmacological characterization of novel β2-adrenoceptor antagonists10.1111/j.1476-5381.2011.01269.x ↗
33. Araujo, N., Ferreira da Silva, A., Qing, Y., Lifino, M., Russell, A.J., Small, B., Wade-Martins, R., and Wynne, G.M. (2015). Therapeutic Compounds. Int. Patent Appl., No. WO 2015/004485 A1.
34. Sheldrick, G.M. (2004). SADABS, Program for Empirical X-ray Absorption Correction, Bruker-Nonius.
35. A short history of SHELX10.1107/S0108767307043930 ↗
36. WinGX suite for small-molecule single-crystal crystallography10.1107/S0021889899006020 ↗
37. Mercury: Visualization and analysis of crystal structures10.1107/S002188980600731X ↗
38. Single-crystal structure validation with the program PLATON10.1107/S0021889802022112 ↗
39. Bruker AXS (2005). DIFFRAC Plus Evaluation package EVA, Version 11. User’s Manual, Bruker AXS.
40. Bruker AXS (2005). TOPAS v3: General profile and structure analysis software for powder diffraction data. Technical Reference, Bruker AXS.
41. EXPO2013: A kit of tools for phasing crystal structures from powder data10.1107/S0021889813013113 ↗
42. Stereochemische Notizen10.1002/cber.19040370313 ↗
43. Jaques, J., Collet, A., and Wilen, S.H. (1981). Enantiomers, Racemates, and Resolutions, J. Wiley and Sons, Inc.
44. Characterization of racemic species of chiral drugs using thermal analysis, thermodynamic calculation, and structural studies10.1021/js980205u ↗
45. From racemic compounds through metastable to stable racemic conglomerates: Crystallization features of chiral halogen and cyano monosubstituted phenyl glycerol ethers10.1016/j.tetasy.2009.09.008 ↗
46. Chiral para-alkyl phenyl ethers of glycerol: Synthesis and testing of chirality driven crystallization, liquid crystal, and gelating properties10.1016/j.tetasy.2013.05.017 ↗
47. Crystallization of chiral para-n-alkylphenyl glycerol ethers: Phase diversity and impressive predominance of homochiral guaifenesin-like supramolecular motif10.1021/acs.cgd.8b00321 ↗
48. Patterns in hydrogen bonding—Functionality and graph set analysis in crystals10.1002/anie.199515551 ↗